Search Results

You are looking at 1 - 10 of 124 items for :

  • "liver metastases" x
  • Refine by Access: All x
Clear All
Full access

A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status

Yoshikuni Kawaguchi, Scott Kopetz, Heather A. Lillemoe, Hyunsoo Hwang, Xuemei Wang, Ching-Wei D. Tzeng, Yun Shin Chun, Thomas A. Aloia, and Jean-Nicolas Vauthey

Background Approximately 15% of patients with colorectal cancer (CRC) have synchronous colorectal liver metastases (CLM; detected at initial diagnosis or during treatment after initial diagnosis), and approximately 30% of patients with CRC have

Full access

Liver-Directed Therapies in Patients With Advanced Neuroendocrine Tumors

Natalie B. Jones, Manisha H. Shah, and Mark Bloomston

cases of NETs Analyze surgical options for the treatment of liver metastases associated with NETs Assess the use of embolization of liver metastases associated with NETs Evaluate other treatment modalities of liver metastases associated with NETs

Full access

Local Therapies for Hepatic Metastases

Fabian M. Johnston, Michael N. Mavros, Joseph M. Herman, and Timothy M. Pawlik

Traditionally, local therapy for hepatic metastases has been largely reserved for patients with colorectal liver metastases (CRLM) or, less often, neuroendocrine liver metastases (NELM). Colorectal cancer is one of the most common types of cancer

Full access

Metastatic Mucinous Ovarian Cancer and Treatment Decisions Based on Histology and Molecular Markers Rather Than the Primary Location

Angela Jain, Paula D. Ryan, and Michael V. Seiden

this point showed that liver metastases had completely calcified without evidence of new disease ( Figure 1 ). With the goal of increasing tumor response, weekly paclitaxel was added to trastuzumab. Over 6 weeks, the CEA continued to trend down to 496

Full access

Role of Interventional Radiology in the Treatment of Patients with Neuroendocrine Metastases in the Liver

Larry K. Kvols, Kiran K. Turaga, Jonathan Strosberg, and Junsung Choi

J Gastroenterol 2005 ; 11 : 7676 – 7683 . 7 Sutcliffe R Maguire D Ramage J . Management of neuroendocrine liver metastases . Am J Surg 2004 ; 187 : 39 – 46 . 8 Pichlmayr R Weimann A Oldhafer KJ . Appraisal of

Full access

Differential Radiographic Appearance of BRAF V600E–Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location

Chloe E. Atreya, Claire Greene, Ryan M. McWhirter, Nabia S. Ikram, I. Elaine Allen, Katherine Van Loon, Alan P. Venook, Benjamin M. Yeh, and Spencer C. Behr

associated with less frequent liver metastases (42% vs 79%; P =.024) and more frequent ascites (58% vs 12%; P =.0038) ( Table 2 ). If rectal tumors were grouped with left-sided primaries, BRAF mutations remained associated with ascites (56% vs 9%; P

Full access

Major Response to Cyclophosphamide and Prednisone in Recurrent Castration-Resistant Prostate Cancer

Nicolas Batty, Naveen Yarlagadda, and Roberto Pili

rapid response of the liver metastases in this patient is intriguing. Anecdotal experience of this drug in patients with CRPC and liver metastases suggests a specific response for these visceral lesions. The reason for the organ-specificity of this

Full access

In Defense of Hepatic Arterial Infusion for Hepatic Metastases of Colorectal Cancer

Nancy Kemeny

) setting to shrink hepatic metastases and make liver resection possible. In several systemic therapy–alone chemotherapy trials for patients with liver metastases that cannot be resected, the rate of conversion to resection is 15% to 30% in chemotherapy

Full access

Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma

Matthew Zibelman and Anthony J. Olszanski

months after initial dose of ipilimumab reveals a marked decrease in size and fludeoxyglucose-avidity of right neck mass and complete resolution of bilateral adrenal and liver metastases (representative images). Discussion This case

Full access

Larotrectinib in a Patient With Advanced Pleomorphic Liposarcoma of the Uterus

Anisley Valenciaga, O. Hans Iwenofu, and Gabriel Tinoco

liver metastases seen in (A) right posterior hepatic lobe measuring 1.9 cm and (B) right inferior lobe measuring 1.1 cm (yellow arrows) while patient received olaratumab maintenance therapy 15 months after initial surgery. The patient was then